STOCK TITAN

Turn Therapeutics (TTRX) Stock News

TTRX NASDAQ

Turn Therapeutics Inc. (Nasdaq: TTRX) is a clinical-stage biotechnology company whose news flow centers on dermatology, advanced wound care, infectious disease therapies, and intranasal vaccine initiatives. Company updates frequently highlight progress in its lead program GX-03, a topical IL-36/IL-31 pathway inhibitor in a phase 2 trial for moderate to severe atopic dermatitis, as well as other late-stage clinical programs in eczema and onychomycosis.

News releases from Turn Therapeutics regularly cover clinical milestones, such as enrollment updates, safety summaries, and timing for interim and topline data from its phase 2 eczema study. Investors and observers can also follow announcements related to its thermostable intranasal vaccine initiative, including stability data for a live, lipid-enveloped vaccine formulated with the PermaFusion platform and the planned in-vivo and in-vitro studies for an intranasal influenza vaccine candidate.

Corporate and strategic developments are another key theme in TTRX news. The company has reported its direct listing on Nasdaq, capital strategy using flexible financing arrangements, and a global supply, development, and license agreement with Medline to develop and commercialize PermaFusion-based products in professional and retail markets. Governance updates, including the appointments of experienced board members and a Vice President of Corporate Communications, also feature prominently.

Turn Therapeutics additionally issues communications on shareholder engagement efforts, such as webinar series and public discussions involving its leadership on topics like healthcare communication and public trust in science. For readers tracking TTRX, this news page offers a centralized view of clinical progress, partnership activity, financing developments, and corporate governance changes over time.

Rhea-AI Summary

Turn Therapeutics (TTRX) announced that CEO Bradley Burnam will present at the Jefferies Global Healthcare Conference in London on November 16, 2026. The presentation runs from 10:30–10:55 AM ET (3:30–3:55 PM GMT) and will cover the GX-03 atopic dermatitis program, including how Phase 2a findings informed the Phase 2b study design. A live webcast and a replay available for approximately 90 days will be accessible through the company website.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary

Turn Therapeutics (TTRX) reported a third-quarter 2026 net loss of $6,230,868 alongside GX-03 clinical updates and accelerated trial plans. Loss per share was $0.21 versus $0.07 a year earlier. Cash was $10,363,975 at September 30; the company expects operations to be funded into the third quarter of 2027.

In the completed 50-patient Stage 1/Phase 2a atopic dermatitis trial, 59.3% of GX-03 patients achieved clear or almost clear skin after four weeks versus 30.4% receiving vehicle. At Week 8, 40.7% had no visible eczema versus 17.4%. Turn expects Phase 2b topline results in the first quarter of 2027 and enrollment in its approximately 80-patient hidradenitis suppurativa trial to begin that quarter, ahead of its previous second-quarter target. Robert R. Redfield was appointed chief scientific officer on September 9, 2026.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.27%
Tags
-
Rhea-AI Summary

Turn Therapeutics (Nasdaq: TTRX) announced that GX-03 won “Developmental Immunology Solution of the Year” in the 2026 BioTech Breakthrough Awards.

GX-03 is an investigational topical treatment for atopic dermatitis, or eczema, undergoing an adaptive Phase 2 trial. Interim Phase 2a results (n=50) showed 59.3% of GX-03 patients achieved clear or almost clear skin within four weeks, versus 30.4% on vehicle, the comparison formulation. At week 8, 40.7% achieved complete clearance measured by the Eczema Area and Severity Index, versus 17.4% on vehicle. Data from the first 50 completers informed changes to Phase 2b enrollment criteria and endpoints to capture activity across a broader severity spectrum. The company plans to expand GX-03 into hidradenitis suppurativa, targeting first patient enrollment in a Phase 2a study in the first quarter of 2027.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.78%
Tags
none
Rhea-AI Summary

Turn Therapeutics (TTRX) will participate in a U.S. Bancorp | BTIG virtual fireside chat on October 28, 2026. CEO Bradley Burnam and Executive Clinical and Regulatory Lead Stephen M. Hahn will discuss development strategy for GX-03, its lead investigational therapy, and patient access in atopic dermatitis. The chat begins at 10:00 AM ET and is open to U.S. Bancorp | BTIG institutional clients.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.30%
Tags
none
-
Rhea-AI Summary

Turn Therapeutics (TTRX) will present at the Stifel 2026 Virtual Immunology and Inflammation Forum on September 23, 2026 at 1:30 PM ET.

The presentation by CEO Bradley Burnam and Executive Clinical and Regulatory Lead Stephen M. Hahn, M.D., will focus on the company’s atopic dermatitis clinical program, including its pruritus-focused stage 2 enrichment strategy and emerging findings across distinct patient populations. These include patients with moderate-severe baseline pruritus and a cohort with lower EASI scores but high investigator-assessed disease severity (IGA). A live webcast will be accessible via the Investors section of the Turn Therapeutics website, with a replay available for approximately six months.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.69%
Tags
none
-
Rhea-AI Summary

Turn Therapeutics (TTRX) appointed Robert R. Redfield, M.D., former Director of the U.S. Centers for Disease Control and Prevention, as Chief Scientific Officer. He brings more than four decades of experience in immunology, microbiology, infectious disease, clinical research, and public health.

Dr. Redfield will help guide scientific and clinical strategy for GX-03 in atopic dermatitis, onychomycosis, hidradenitis suppurativa and potential additional indications, with a focus on cytokine signaling and host inflammatory responses. GX-03 is being evaluated in atopic dermatitis, where preclinical work showed effects on inflammatory mediators and interim data suggested strong efficacy and safety, and is also being developed for onychomycosis.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.61%
Tags
none
Rhea-AI Summary

NovaBridge Biosciences (NBP) appointed Martin Dewhurst as an independent director on its Board on September 8, 2026.

Dewhurst will also serve on NovaBridge’s Audit Committee and Compensation Committee, effective immediately. He brings more than 30 years of leadership, governance, and strategic advisory experience across biotech, biopharma, medical devices, health tech, and healthcare investment, including over three decades at McKinsey & Company, where he co-led the Global Life Sciences Practice and co-founded the McKinsey Health Institute. His appointment follows the departure of independent director Liu Xin from the Board. Dewhurst currently holds multiple board and advisory roles in healthcare companies and investment firms.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
29.18%
Tags
management
-
Rhea-AI Summary

Turn Therapeutics (Nasdaq:TTRX) reported new peer-reviewed in-vivo data showing its topical investigational therapy GX-03 selectively reduced key inflammatory cytokines and disease severity in a murine model of atopic dermatitis-like inflammation. The study in the journal Life evaluated 40 mice pretreated for four days with GX-03 or left untreated before standardized Staphylococcus aureus skin exposure. After exclusions, 18 animals per group were analyzed.

According to Turn Therapeutics, GX-03 pretreatment reduced mean vIGA-AD disease severity from 2.44 in untreated animals to 0.83, a 66.0% reduction. IL-36α fell by 49.9%, IL-36γ by 50.9%, IL-31 by 67.7%, and IL-4 by 16.7%, while IL-13 remained essentially unchanged, indicating a selective cytokine pattern. No local irritation, dryness, redness, barrier disruption or other adverse skin findings were reported during pretreatment. The study was conducted at Altogen Labs under an IACUC-approved protocol. GX-03 is being developed as a localized, non-systemic treatment for atopic dermatitis and is currently in a randomized, double-blind, vehicle-controlled clinical trial.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.85%
Tags
none
-
Rhea-AI Summary

Turn Therapeutics (Nasdaq:TTRX) reported second quarter 2026 results and clinical updates for GX-03 in atopic dermatitis. An interim analysis of the ongoing Phase 2 trial, completed July 7, 2026, supported expanding Stage 2 enrollment to approximately 120–135 patients with moderate-to-severe lesions but broader disease extent.

According to Turn Therapeutics, GX-03 showed treatment separation from vehicle across four preselected efficacy endpoints, with up to 61.5% vs 8.3% achieving clear or almost clear skin at Week 4 and 46.2% vs 8.3% achieving EASI-100 at Week 8. Stage 1 showed no serious adverse events or discontinuations.

The company appointed former FDA Commissioner Stephen M. Hahn, M.D. as Executive Clinical and Regulatory Lead, published its first peer-reviewed preclinical GX-03 data, and plans a Phase 2a GX-03 study in hidradenitis suppurativa, targeting first patient dosing in Q2 2027.

Turn Therapeutics ended June 30, 2026 with $10.3 million in cash and cash equivalents and reported a Q2 2026 net loss of $5.85 million. The company estimates its cash will fund operations, including the Phase 2 atopic dermatitis trial, into the third quarter of 2027.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.45%
Tags
Rhea-AI Summary

Turn Therapeutics (Nasdaq: TTRX) announced that Founder and CEO Bradley Burnam and members of the management team will ring the Nasdaq Closing Bell on Monday, August 10, 2026, at Nasdaq MarketSite in Times Square, New York, at Nasdaq's invitation to recognize the company's progress since its October 2025 direct listing.

The bell-ringing ceremony will be broadcast live beginning at 3:45 p.m. ET via Nasdaq's livestream. Turn Therapeutics is a clinical-stage biotechnology company developing targeted, localized, non-systemic therapies for inflammatory and infectious skin diseases. Its lead investigational topical candidate, GX-03, is being developed for atopic dermatitis and is designed to achieve biologic-level efficacy without injectable administration or systemic immunosuppression.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.03%
Tags
none

FAQ

What is the current stock price of Turn Therapeutics (TTRX)?

Turn Therapeutics (TTRX) last closed at $8.55.

What is the market cap of Turn Therapeutics (TTRX)?

The market cap of Turn Therapeutics (TTRX) is approximately $261.4M.